Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide versus placebo in children aged 2 to 5 years with functional constipation
NL-OMON58812Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linaclotide in functional constipation (FC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Change from baseline in 12-week spontaneous bowel movement frequency rate. Started Apr 2024; status: completed.
02
Drugs
linaclotide
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on NL-OMON58812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58812.